Which has preferable valuation & earnings, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.47M 94.77 -$67.85M -$0.24 N/A Moderna $2.21B 9.90 -$2.82B -$7.99 N/A

Is OCGN or MRNA more profitable?

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Moderna -141.43% -28.30% -19.39%

Does the media refer more to OCGN or MRNA?

In the previous week, Moderna had 41 more articles in the media than Ocugen. MarketBeat recorded 49 mentions for Moderna and 8 mentions for Ocugen. Ocugen's average media sentiment score of 0.68 beat Moderna's score of 0.38 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 17 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, PFE or OCGN?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $63.31B 2.25 $7.77B $1.31 19.12 Ocugen $4.47M 94.77 -$67.85M -$0.24 N/A

Is PFE or OCGN more profitable?

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Ocugen N/A -127,987.80% -135.48%

Does the media refer more to PFE or OCGN?

In the previous week, Pfizer had 61 more articles in the media than Ocugen. MarketBeat recorded 69 mentions for Pfizer and 8 mentions for Ocugen. Pfizer's average media sentiment score of 0.77 beat Ocugen's score of 0.68 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 38 Very Positive mention(s) 10 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Ocugen 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABCL or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets AbCellera Biologics -181.75% -14.86% -10.62% Ocugen N/A -127,987.80% -135.48%

Does the media refer more to ABCL or OCGN?

In the previous week, Ocugen had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Ocugen and 3 mentions for AbCellera Biologics. Ocugen's average media sentiment score of 0.68 beat AbCellera Biologics' score of 0.13 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, OCGN or TRLV?

Trulieve Cannabis has higher revenue and earnings than Ocugen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.47M 94.77 -$67.85M -$0.24 N/A Trulieve Cannabis $1.17B 1.41 N/A N/A N/A

Is OCGN or TRLV more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% Trulieve Cannabis N/A N/A N/A

Does the media favor OCGN or TRLV?

In the previous week, Ocugen had 7 more articles in the media than Trulieve Cannabis. MarketBeat recorded 8 mentions for Ocugen and 1 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 1.94 beat Ocugen's score of 0.68 indicating that Trulieve Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trulieve Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, OCGN or ANAB?

AnaptysBio has higher revenue and earnings than Ocugen. AnaptysBio is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.47M 94.77 -$67.85M -$0.24 N/A AnaptysBio $234.60M 6.77 -$13.23M -$1.08 N/A

Is OCGN or ANAB more profitable?

Ocugen has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -135.48% AnaptysBio -11.53% N/A -7.75%

Does the media prefer OCGN or ANAB?

In the previous week, Ocugen had 4 more articles in the media than AnaptysBio. MarketBeat recorded 8 mentions for Ocugen and 4 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.29 beat Ocugen's score of 0.68 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ocugen (OCGN) Competitors

$1.25 +0.02 (+1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.01 (+0.80%)

As of 05:11 PM Eastern

Compare

OCGN vs. MRNA, PFE, ABCL, TRLV, and ANAB

Should you buy Ocugen stock or one of its competitors? MarketBeat compares Ocugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocugen include Moderna (MRNA), Pfizer (PFE), AbCellera Biologics (ABCL), Trulieve Cannabis (TRLV), and AnaptysBio (ANAB).

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Ocugen presently has a consensus price target of $9.50, indicating a potential upside of 660.00%. Moderna has a consensus price target of $42.13, indicating a potential downside of 23.59%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts plainly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Moderna	-141.43%	-28.30%	-19.39%

In the previous week, Moderna had 41 more articles in the media than Ocugen. MarketBeat recorded 49 mentions for Moderna and 8 mentions for Ocugen. Ocugen's average media sentiment score of 0.68 beat Moderna's score of 0.38 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ocugen has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	94.77	-$67.85M	-$0.24	N/A
Moderna	$2.21B	9.90	-$2.82B	-$7.99	N/A

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ocugen beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Pfizer (NYSE:PFE) and Ocugen (NASDAQ:OCGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.25	$7.77B	$1.31	19.12
Ocugen	$4.47M	94.77	-$67.85M	-$0.24	N/A

In the previous week, Pfizer had 61 more articles in the media than Ocugen. MarketBeat recorded 69 mentions for Pfizer and 8 mentions for Ocugen. Pfizer's average media sentiment score of 0.77 beat Ocugen's score of 0.68 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	38 Very Positive mention(s)	10 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Ocugen	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Ocugen	N/A	-127,987.80%	-135.48%

Pfizer presently has a consensus price target of $28.50, suggesting a potential upside of 13.77%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 660.00%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Pfizer beats Ocugen on 11 of the 16 factors compared between the two stocks.

How does Ocugen compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AbCellera Biologics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

AbCellera Biologics presently has a consensus price target of $8.00, suggesting a potential upside of 37.22%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 660.00%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ocugen has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Ocugen	N/A	-127,987.80%	-135.48%

Ocugen has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$79.21M	22.48	-$146.41M	-$0.48	N/A
Ocugen	$4.47M	94.77	-$67.85M	-$0.24	N/A

In the previous week, Ocugen had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Ocugen and 3 mentions for AbCellera Biologics. Ocugen's average media sentiment score of 0.68 beat AbCellera Biologics' score of 0.13 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ocugen beats AbCellera Biologics on 10 of the 17 factors compared between the two stocks.

How does Ocugen compare to Trulieve Cannabis?

Ocugen (NASDAQ:OCGN) and Trulieve Cannabis (NYSE:TRLV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, Ocugen had 7 more articles in the media than Trulieve Cannabis. MarketBeat recorded 8 mentions for Ocugen and 1 mentions for Trulieve Cannabis. Trulieve Cannabis' average media sentiment score of 1.94 beat Ocugen's score of 0.68 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trulieve Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Trulieve Cannabis has higher revenue and earnings than Ocugen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	94.77	-$67.85M	-$0.24	N/A
Trulieve Cannabis	$1.17B	1.41	N/A	N/A	N/A

10.3% of Ocugen shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 3.8% of Trulieve Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 660.00%. Trulieve Cannabis has a consensus target price of $15.00, suggesting a potential upside of 75.42%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Trulieve Cannabis' return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
Trulieve Cannabis	N/A	N/A	N/A

Summary

Ocugen beats Trulieve Cannabis on 7 of the 11 factors compared between the two stocks.

How does Ocugen compare to AnaptysBio?

Ocugen (NASDAQ:OCGN) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

10.3% of Ocugen shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 31.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AnaptysBio has higher revenue and earnings than Ocugen. AnaptysBio is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	94.77	-$67.85M	-$0.24	N/A
AnaptysBio	$234.60M	6.77	-$13.23M	-$1.08	N/A

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 660.00%. AnaptysBio has a consensus price target of $82.00, suggesting a potential upside of 52.81%. Given Ocugen's higher possible upside, equities research analysts plainly believe Ocugen is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ocugen has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-135.48%
AnaptysBio	-11.53%	N/A	-7.75%

In the previous week, Ocugen had 4 more articles in the media than AnaptysBio. MarketBeat recorded 8 mentions for Ocugen and 4 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.29 beat Ocugen's score of 0.68 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Summary

Ocugen and AnaptysBio tied by winning 8 of the 16 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$423.15M	$3.51B	$6.81B	$12.69B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-5.21	7.34	281.03	25.13
Price / Sales	94.77	1,215.58	574.87	80.86
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-31.25	16.89	11.03	6.21
Net Income	-$67.85M	-$12.54M	$3.48B	$347.60M
7 Day Performance	-0.79%	-0.63%	0.54%	0.88%
1 Month Performance	-17.22%	-7.39%	-4.19%	-3.62%
1 Year Performance	25.81%	49.17%	63.11%	20.46%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	2.375 of 5 stars	$1.25 +1.6%	$9.50 +660.0%	+23.8%	$423.15M	$4.47M	N/A	80	Upcoming Earnings
MRNA Moderna	1.3725 of 5 stars	$55.63 +2.9%	$40.00 -28.1%	+98.6%	$21.45B	$1.94B	N/A	4,700	Earnings Report Analyst Forecast Options Volume Analyst Revision
PFE Pfizer	4.1566 of 5 stars	$24.68 +0.6%	$28.50 +15.5%	+6.9%	$139.86B	$62.58B	18.84	75,000	Trending News Upcoming Earnings Analyst Upgrade
ABCL AbCellera Biologics	2.6121 of 5 stars	$5.25 -1.1%	$8.00 +52.4%	+34.7%	$1.62B	$75.13M	N/A	500	Positive News Upcoming Earnings
TRLV Trulieve Cannabis	3.7993 of 5 stars	$8.33 -0.4%	$15.00 +80.1%	N/A	$1.61B	$1.17B	N/A	9,000	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors